SUPT16H

Across TCGA pan-cancer cohorts, SUPT16H mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUPT16H data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SUPT16H mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUPT16H expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where SUPT16H mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.661	0.932	.002	45	view →
LSCC	DFS	Median	II,III,IV	0.863	0.517	<.001	23	view →
LUAD	DFS	Quartile	II,III,IV	0.994	0.676	.002	15	view →
UCEC	DFS	Tertile	All	0.865	0.985	.029	2	view →
CCRCC	OS	Tertile	All	0.756	1.000	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SUPT16H–HNSC (DFS)

Open the HNSC breakdown →